...
首页> 外文期刊>Eye >Intermediate outcomes of Ahmed glaucoma valve surgery in Asian patients with intractable glaucoma.
【24h】

Intermediate outcomes of Ahmed glaucoma valve surgery in Asian patients with intractable glaucoma.

机译:亚洲顽固性青光眼患者的艾哈迈德青光眼瓣膜手术的中期结局。

获取原文
获取原文并翻译 | 示例

摘要

OBJECTIVE: To evaluate the efficacy and safety of Ahmed glaucoma valve (AGV) implantation in Asian patients with refractory glaucoma. METHODS: The study was a retrospective interventional case series conducted at a single institution between January 2004 and January 2006. The study population included 91 patients (91 eyes). RESULTS: A total of 70 patients were successfully treated (74.5%). Postoperatively, the median intraocular pressures declined significantly to 13 mm Hg (interquartile range: 10-20 mm Hg) on day 1 (P<0.001) and 17 mm Hg (interquartile range: 12-19 mm Hg) at the last follow-up examination (P<0.001). The cumulative probability of success according to Kaplan-Meier life-table analysis was 74% at 12 months and 43% at 2 years. Hazard of failure increased slightly with age, HR: 1.03 (95% confidence interval (CI)=1.00-1.05; P=0.044). The most common complication was hyphaemia at 12.77%. There were no serious complications involving loss of visual acuity or sight. CONCLUSIONS: AGV implantation is an acceptable treatment for refractory glaucoma in high-risk patients with few additional options.
机译:目的:评估艾哈迈德青光眼瓣膜植入术在亚洲难治性青光眼患者中的疗效和安全性。方法:该研究是回顾性干预病例系列,于2004年1月至2006年1月在单个机构进行。研究人群包括91例患者(91眼)。结果:共成功治愈70例患者(74.5%)。术后第一天的中位眼压显着下降至第1天的13 mm Hg(四分位间距:10-20 mm Hg)(P <0.001)和最后一次随访时的17 mm Hg(四分位间距:12-19 mm Hg)检查(P <0.001)。根据Kaplan-Meier生命表分析,成功的累积概率在12个月时为74%,在2年时为43%。失败的风险随着年龄的增长而略有增加,HR:1.03(95%置信区间(CI)= 1.00-1.05; P = 0.044)。最常见的并发症是血友病,占12.77%。没有严重的并发症涉及视力或视力丧失。结论:AGV植入是高危患者难治性青光眼的可接受治疗方法,几乎​​没有其他选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号